Muge Celiktas
Muge Celiktas
The University of Texas MD Anderson Cancer Center
Verified email at mdanderson.org
Title
Cited by
Cited by
Year
Stability of the hybrid epithelial/mesenchymal phenotype
MK Jolly, SC Tripathi, D Jia, SM Mooney, M Celiktas, SM Hanash, ...
Oncotarget 7 (19), 27067, 2016
2062016
Metastatic progression of prostate cancer and e-cadherin: Regulation by Zeb1 and Src family kinases
AP Putzke, AP Ventura, AM Bailey, C Akture, J Opoku-Ansah, M Çeliktaş, ...
The American journal of pathology 179 (1), 400-410, 2011
1192011
Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival
MJ Schliekelman, A Taguchi, J Zhu, X Dai, J Rodriguez, M Celiktas, ...
Cancer research 75 (9), 1789-1800, 2015
1182015
Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome
SC Tripathi, HL Peters, A Taguchi, H Katayama, H Wang, A Momin, ...
Proceedings of the National Academy of Sciences 113 (11), E1555-E1564, 2016
962016
MCAM mediates chemoresistance in small-cell lung cancer via the PI3K/AKT/SOX2 signaling pathway
SC Tripathi, JF Fahrmann, M Celiktas, M Aguilar, KD Marini, MK Jolly, ...
Cancer research 77 (16), 4414-4425, 2017
402017
Distinguishing mechanisms underlying EMT tristability
D Jia, MK Jolly, SC Tripathi, P Den Hollander, B Huang, M Lu, M Celiktas, ...
Cancer convergence 1 (1), 2, 2017
392017
Role of CPS1 in cell growth, metabolism, and prognosis in LKB1-inactivated lung adenocarcinoma
M Çeliktaş, I Tanaka, S Chandra Tripathi, JF Fahrmann, ...
JNCI: Journal of the National Cancer Institute 109 (3), 2017
312017
A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic targets
A Taguchi, AD Taylor, J Rodriguez, M Çeliktaş, H Liu, X Ma, Q Zhang, ...
Cancer research 74 (17), 4694-4705, 2014
282014
Proteomic signatures associated with p53 mutational status in lung adenocarcinoma
A Taguchi, O Delgado, M Çeliktaş, H Katayama, H Wang, AF Gazdar, ...
Proteomics 14 (23-24), 2750-2759, 2014
182014
Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget. 2016; 7: 27067–84
MK Jolly, SC Tripathi, D Jia, SM Mooney, M Celiktas, SM Hanash, ...
8
Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget. 2016; 7 (19): 27067–84
MK Jolly, SC Tripathi, D Jia, SM Mooney, M Celiktas, SM Hanash, ...
PubMed Abstract| Publisher Full Text| Free Full Text| F1000 Recommendation, 0
4
Loss of immunoproteasome driven by EMT is associated with immune evasion and poor prognosis in non-small cell lung cancer
SC Tripathi, HL Peters, A Taguchi, H Katayama, H Wang, A Momin, ...
Journal of Thoracic Oncology 11 (2), S48-S49, 2016
12016
CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes
M Capello, JF Fahrmann, MV Rios Perez, JV Vykoukal, E Irajizad, ...
JCO Precision Oncology 4, 426-436, 2020
2020
Aberrant tryptophan catabolism marked by high kynureninase expression contributes to immunosuppression and poor outcome in lung adenocarcinoma
EJ Ostrin, JF Fahrmann, I Tanaka, M Celiktas, C Aguilar, M Aguilar, ...
Cancer Research 78 (13 Supplement), 1447-1447, 2018
2018
MCAM modulates small cell lung cancer chemoresistance via PI3k/Akt/Sox2 signaling pathway
SC Tripathi, JF Fahrmann, M Celiktas, M Aguilar, KD Marini, MK Jolly, ...
Cancer Research 77 (13 Supplement), 3170-3170, 2017
2017
CPS1 as a therapeutic target and prognostic indicator in LKB1-inactivated lung adenocarcinoma
M Celiktas, I Tanaka, SC Tripathi, JF Fahrmann, C Aguilar-Bonavides, ...
Cancer Research 77 (13 Supplement), 2775-2775, 2017
2017
Stability and stemness of the hybrid epithelial-mesenchymal phenotype
MK Jolly, D Jia, SC Tripathi, S Mooney, M Celiktas, SM Hanash, SA Mani, ...
Cancer Research 77 (13 Supplement), 3053-3053, 2017
2017
Immunoproteasome Deficiency In Non-Small Cell Lung Cancer Is Associated With Mesenchymal Phenotype, Restricted Antigen Presentation, And Poor Outcome
EJ Ostrin, S Tripathi, HL Peters, A Taguchi, MJ Schliekelman, H Katayama, ...
D99. NOVEL TRANSLATIONAL BIOMARKERS IN LUNG CANCER, A7540-A7540, 2016
2016
Immunoproteasome deficiency is a feature of NSCLC with a mesenchymal phenotype and is associated with restricted antigen presentation and poor outcome in patients
SC Tripathi, HL Peters, EJ Ostrin, A Taguchi, H Katayama, H Wang, ...
CANCER IMMUNOLOGY RESEARCH 4 (1), 2016
2016
D99 NOVEL TRANSLATIONAL BIOMARKERS IN LUNG CANCER: Immunoproteasome Deficiency In Non-Small Cell Lung Cancer Is Associated With Mesenchymal Phenotype, Restricted Antigen …
EJ Ostrin, S Tripathi, HL Peters, A Taguchi, MJ Schliekelman, H Katayama, ...
American Journal of Respiratory and Critical Care Medicine 193, 1, 2016
2016
The system can't perform the operation now. Try again later.
Articles 1–20